2024 World Conference on Lung Cancer (WCLC) - Posters-P1.06B.10 Post-hoc Biomarker Analysis of Adebrelimab Plus Chemotherapy and Sequential Radiotherapy as First-Line Therapy for ES-SCLC

P1.06B.10 Post-hoc Biomarker Analysis of Adebrelimab Plus Chemotherapy and Sequential Radiotherapy as First-Line Therapy for ES-SCLC

Back to course

Pdf Summary

A post-hoc analysis of a clinical trial (NCT04562337) evaluated biomarkers associated with the therapeutic efficacy of adebrelimab combined with chemotherapy and sequential thoracic radiotherapy (TRT) in patients with extensive-stage small cell lung cancer (ES-SCLC). The study, conducted by researchers from Shandong Cancer Hospital and Institute and other collaborating institutions, included 67 patients, with biospecimens collected from 55 for comprehensive analysis.<br /><br />The exploratory study involved genomic profiling using the AmoyDx Master Panel on tissue samples and cell-free DNA (cfDNA) covering 571 cancer-related genes. Transcriptomic analysis was also conducted on tissue and peripheral blood mononuclear cells (PBMC) using RNA sequencing.<br /><br />Key findings from the study showed the identification of genomic and transcriptomic biomarkers that correlated with clinical benefits from the treatment regimen. Specifically, the YAP1 subtype and overexpression were linked with a better prognosis for patients undergoing adebrelimab plus chemotherapy and TRT. Additionally, high expression levels of CD274 (PD-L1) were associated with prolonged progression-free survival (PFS) in patients receiving the treatment.<br /><br />Transcriptomic clustering of PBMC revealed distinct prognostic patterns for treatment response. Notably, regulatory T cell signatures and ZNF683CD8 T cell involvement were highlighted in different patient clusters, potentially differentiating patient responses to the combined therapy.<br /><br />The results provide insights into the molecular and immune profiles that could predict response to this first-line treatment approach in ES-SCLC. However, further validation of these biomarkers in additional studies is needed to substantiate their clinical utility.

Asset Subtitle

Changbin Zhu

Meta Tag

Speaker Changbin Zhu

Topic Pathology & Biomarkers

Keywords

post-hoc analysis

clinical trial

biomarkers

adebrelimab

chemotherapy

thoracic radiotherapy

small cell lung cancer

genomic profiling

transcriptomic analysis

immune profiles